Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Astellas acquired Audentes Therapeutics for ~$3B for gene therapy.
Astellas to acquire gene therapy firm Audentes for $3 billion, adding a fifth Primary Focus Area in Genetic Regulation and positioning itself as a global…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Astellas acquired Audentes Therapeutics for ~$3B for gene therapy.
200 US cases/yr · $2.0B Global Pompe Disease Market (2024)
Pompe disease is a rare lysosomal storage disorder caused by GAA enzyme deficiency, leading to progressive muscle weakness. Standard of care is enzyme replacement therapy (ERT: Lumizyme/Myozyme by Sanofi, Nexviazyme by Amicus). Gene therapy aims to provide endogenous GAA production.
Astellas/Audentes AT845 is an AAV gene therapy for Pompe. Competitors: Asklepios (AAV), Sarepta (AAV), Spark/Roche (preclinical). The challenge is achieving sufficient GAA expression in skeletal muscle, heart, and diaphragm. ERT remains standard but requires lifelong biweekly infusions, creating strong rationale for gene therapy.
40 US cases/yr · $100M Estimated Market Opportunity
X-linked myotubular myopathy (XLMTM) is an ultra-rare neuromuscular disorder affecting ~1 in 50,000 male births. Most affected boys require ventilatory support; ~25% die in the first year. AT132 (resamirigene bilparvovec) was placed on clinical hold after patient deaths from hepatotoxicity.
AT132 was a promising AAV8 gene therapy for XLMTM but patient deaths from hepatotoxicity in boys with pre-existing liver disease led to clinical holds and regulatory scrutiny. This highlighted safety risks of high-dose systemic AAV gene therapy, particularly in patients with hepatobiliary disease. Astellas paid ~$3B for Audentes based on this program.
Astellas completed ~$3B acquisition of Audentes Therapeutics, gaining AT132 gene therapy for X-linked myotubular myopathy and broader gene therapy platform.
FDA placed clinical hold on AT132 after patient deaths in ASPIRO trial, raising serious safety concerns about AAV gene therapy at high doses.
Astellas halted AT132 (AAV8 gene therapy for X-linked myotubular myopathy) after four pediatric deaths linked to hepatobiliary events in Phase 1/2. Lead asset from $3B Audentes acquisition failed.
Audentes acquisition suffered major setbacks with patient deaths halting lead program. Astellas continues investing but $3B deal has yet to deliver commercial value.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Audentes Therapeutics (this deal) | 2019 | $3.0B | 23 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
← Browse all deals · How we score deals
More: 2019 deals · Astellas Pharma Inc. deals · Gene Therapy deals